An interventional study of Exercise plus Mediterranean diet and At-home exercise plus Mediterranean diet in MASLD, sponsored by Fundación Pública Andaluza para la gestión de la Investigación en Sevilla. Completed at 2 sites in Spain. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-08.
Sponsored by Fundación Pública Andaluza para la gestión de la Investigación en Sevilla · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 28 studies in Fatty Liver with a site in Spain — 11 open to participants now, 12 under way, 4 of them phase 3. Fatty Liver · Spain.
Among the 28 studies in Fatty Liver with a site in Spain, this one is the 14th largest by enrollment of the 23 interventional ones that give a count, is one of 2 that started in 2022, is one of 12 with no phase, and was the 27th registered.
666 studies on the registry are indexed under Fatty Liver; 188 are open to participants now.
Browse Fatty Liver studies →11 of the 28 studies in Fatty Liver with a site in Spain are open now. Recruiting first, the newest first:
Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau · Sites in Spain
Ages 20–80
Consorcio Centro de Investigación Biomédica en Red (CIBER) · Sites in Spain
Ages 40+
Eli Lilly and Company · Sites in Spain, United States, Argentina and 31 more countries
Ages 18+
Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau · Sites in Spain
Ages 18–75
Boehringer Ingelheim · Sites in Spain, United States, Argentina and 34 more countries
Ages 18+
A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →
Of the 118 Fatty Liver studies recruiting now, 36 (31%) set no upper age limit and 63 (53%) stop at 75 or younger; 8 take children under 18; 32 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
28 studies; the count open now beside each. This study's row is marked.
First in 2006; this study’s year is marked. 2 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 96 is above the median of 60 across 434 interventional studies indexed under Fatty Liver.
Median enrollment 165 across the 23 interventional studies, 450 across the 5 observational. Of the 13 that completed or were terminated, 3 (23%) have results posted.
This tab as a report to print or save as PDF → With an account.
11 of 28 have an industry lead sponsor. The 10 most frequent:
Fundación Pública Andaluza para la gestión de la Investigación en Sevilla is the lead sponsor of 120 studies on the registry; 26 are open to participants now.
Fundación Pública Andaluza para la gestión de la Investigación en Sevilla has 1 study filed under Fatty Liver — fewer than ten, so there is no comparison to draw.
3 of the studies in Fatty Liver with a site in Spain that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07652892Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant PauImpact of Steatotic Liver Disease Associated With Metabolic Dysfunction (MASLD) on Frailty, Cognition, and Quality of Life. A Gender-sensitive Approach Towards a Comprehensive and Equitable Perspective. | 2027-02-25 |
| NCT07467512Consorcio Centro de Investigación Biomédica en Red (CIBER)Exercise for an Aging Liver (EXALIVER) | 2027-06 |
| NCT06613698GlaxoSmithKlineA Study to Investigate the Safety and Efficacy of GSK4532990 Compared With Placebo in Adult Participants Aged 18 to 70 Years With Alcohol-related Liver Disease | 2027-11-26 |
Add all 3 to your calendar (.ics) → With an account.
Among the 28 studies in Fatty Liver with a site in Spain, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Lifestyle interventions based on diet and physical activity are the cornerstone of management for metabolic dysfunction-associated steatotic liver disease (MASLD), yet individual responses remain highly variable. Advanced imaging biomarkers and genetic profiling may help to characterize response patterns. This study aimed to evaluate the impact of a Mediterranean diet-based lifestyle intervention, with or without structured physical activity, on liver steatosis and fibrosis assessed by magnetic resonance imaging, and to identify determinants of treatment response.
This randomized controlled trial included adults with histologically confirmed metabolic dysfunction-associated steatotic liver disease (MASLD) recruited between June 2022 and February 2023 at two tertiary referral centres in Spain (Virgen del Rocío University Hospital, Seville, and University Hospital of Valladolid). Exclusion criteria included other causes of chronic liver disease, excessive alcohol intake (>20 g/day in women and >30 g/day in men) , inability to perform regular physical activity, current participation in other clinical trials, and use of steatogenic or investigational drugs.
At the screening visit, all patients received counselling to follow a Mediterranean diet enriched with extra virgin olive oil. Participants were then randomized 1:1 to a structured physical activity programme (exercise group) or to a control group receiving standard lifestyle recommendations during a 12-week active intervention period. Randomization was performed using a computer-generated sequence with concealed allocation. This was followed by a further 12-week observation phase without supervised intervention, with a total follow-up period of 24 weeks, designed to reflect real-life clinical practice.
The sample size was calculated based on the primary endpoint of steatosis improvement. Assuming an absolute difference of 30% between groups, with a two-sided α level of 0.05 and 80% power, a minimum of 36 patients per group was required. To account for an anticipated dropout rate of 20%, the target sample size was increased to 45 patients per group.
The study protocol was approved by the local ethics committees of both centres, and all participants provided written informed consent. The study was conducted in accordance with the Declaration of Helsinki and Good Clinical Practice guidelines.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Supervised exercise programme consisting of moderate-intensity aerobic activity and resistance training three times per week at a sports centre.
Behavioral: Exercise plus Mediterranean diet
The control group was advised to perform moderate-intensity physical activity at home according to EASL recommendations
Behavioral: At-home exercise plus Mediterranean diet
Supervised exercise programme consisting of moderate-intensity aerobic activity and resistance training three times per week at a sports centre, plus counselling to follow a Mediterranean diet enriched with extra virgin olive oil.
Moderate-intensity physical activity at home according to EASL recommendations, plus counselling to follow a Mediterranean diet enriched with extra virgin olive oil.
Steatosis response
Defined as a ≥30% reduction in MRI-proton density fat fraction (PDFF) from baseline to week 24
Time frame: From baseline to week 24
Fibrosis regression
≥20% reduction in liver stiffness measured by MRE or improvement of at least one fibrosis stage
Time frame: Frome baseline to week 24
% Change in Weight
Weight measured in kilograms
Time frame: From baseline to week 24
% Change in Waist Circumference
Waist circumference measured in centimeters
Time frame: From baseline to week 24
% Change in Fat Mass
Fat mass measured in % by impedanciometry
Time frame: From baseline to week 24
% Change in Muscle Mass
Muscle mass measured in % by impedanciometry
Time frame: From baseline to week 24
% Change in Fasting Triglycerides
Triglycerides measured in mg/dL in blood test
Time frame: From baseline to week 24
% Change in Fasting Aspartate Transaminase
Aspartate transaminase measured in U/L in blood test
Time frame: From baseline to week 24
% Change in Fasting Alanine Transaminase
Alanine transaminase measured in U/L in blood test
Time frame: From baseline to week 24
% Change in Fasting Glycosylated Haemoglobin
Glycosylated haemoglobin measured in % in blood test
Time frame: From baseline to week 24
Change in Patient Reported Diet Habits by MEDAS Questionnaire
Assessment of patient reported diet habits using the MEDAS questionnaire, a validated 14-item questionnaire of Mediterranean Diet adherence. Score lower than 9 means low adherence to Mediterranean Diet, and score equal or higher than 9 means good adherence to Mediterranean Diet.
Time frame: From baseline to week 24
Change in Patient Reported Diet Habits by Dietary Items Recount
Assessment of patient reported diet habits using the Dietary Items Recount survey (units/week), that quantifies average consumption of specific foods or beverages over a seven-day period.
Time frame: From baseline to week 24
Change in Exercise Tolerance
Assessment of exercise tolerance and functional capacity using the 6-minute walk test (6MWT). The 6MWT is a functional, submaximal exercise test that measures the maximum distance in meters a person can walk at fastest speed on a flat, hard surface in 6 minutes.
Time frame: From baseline to week 24
Change in Patient Reported Physical Activity
Assessment of patient reported physical activity using the International Physical Activity Questionnaire (IPAQ) questionnaire. IPAQ classifies individuals into three categories based on their total Metabolic Equivalent of Task (MET) minutes per week. Low physical activity: Less than 600 MET-minutes/week; moderate physical activity: Between 600 and 3,000 MET-minutes/week; or high physical activity: More than 3,000 MET-minutes/week.
Time frame: From baseline to week 24
Change in Patient Reported Individual Functioning
Assessment of individual functioning using the SF-12 questionnaire, a 12-item, patient-reported, validated questionnaire assessing Health-Related Quality of Life (HRQoL) across eight physical and mental domains. It covers physical functioning, role-physical, bodily pain, general health, vitality, social functioning, role-emotional, and mental health.
Time frame: From baseline to week 24
Change in Patient Reported Quality of Life
Assessment of patient reported quality of life using the CLDQ-NAFLD Questionnaire, a 36-item, validated, disease-specific questionnaire that assesses patient reported outcomes over the past two weeks across six domains: abdominal symptoms, activity/energy, emotional health, fatigue, systemic symptoms, and worry.
Time frame: From baseline to week 24
Genetic Analysis
Rate of patients (in %) carrying different polymorphisms. The genotyping of the single nucleotide polymorphisms (SNP) of interest, PNPLA3 rs738409, HSD17B13 rs72613567, TM6SF2 rs58542926, FUT2 rs601338, MBOAT7 rs641738 and GCKR rs1260326, was performed using TaqMan SNP genotyping assays and chemistries (ThermoFisher, USA).
Time frame: At baseline
Ran from Jun 2022 to primary completion in Sep 2023, 15 months.
Of 136 non-industry interventional studies with no phase under Fatty Liver, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 40. This study's 15 months is below that.
Counting every sponsor, half of 145 studies reached it within 21 months; a quarter within 10 and three quarters within 39.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 8, 2026: primary completion Feb 2023 → Sep 2023 and completion Apr 2024 → Oct 2023.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Fundación Pública Andaluza para la gestión de la Investigación en Sevilla →